Previous 10 | Next 10 |
Concurrent C$12.5 Million Bought Deal Equity Financing Toronto, Ontario--(Newsfile Corp. - November 28, 2023) - Nighthawk Gold Corp. (TSX: NHK) (OTCQX: MIMZF) (" Nighthawk ") and Moneta Gold Inc. (TSX: ME) (OTCQX: MEAUF) (FSE: MOPA) (" Moneta ") (together, the " Companies ") are pleased to a...
2023-11-25 09:45:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you’re searching for digital health stocks to add to your portfolio, look no further. Technological innovation is leading to the increased digitalization and personalization of health...
2023-11-08 20:18:05 ET 23andMe Holding Co. (ME) Q2 2024 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Ian Cooney - Senior Director, IR Anne Wojcicki - Chief Executive Officer and Co-Founder Joseph Selsavage - Interim Chief Financial an...
2023-11-08 16:14:52 ET 23andMe press release ( NASDAQ: ME ): Q2 GAAP EPS of -$0.16. Revenue of $50M (-34.2% Y/Y). Revenue guidance for FY2024, which will end on March 31, 2024, is adjusted to be in the range of $240 million to $250 million, with net loss reaffirmed to ...
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the second quarter of fiscal year 2024 (FY24), which ended September 30, 2023. Recent Highlights ...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
23andMe Holding Co. (ME) is expected to report for Q1 2024
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, today launched 23andMe+ Total Health , its new, comprehensive prevention-based health membership that provides clinical grade ...
23andMe presented data from the now completed dose escalation phase, and pharmacokinetic / pharmacodynamic (PK/PD) cohorts at the Society for Immunotherapy of Cancer Annual Meeting 2023 Dosing with 23ME-00610 monotherapy in 28 patients with advanced solid tumors up to 1400 mg every th...
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, today launched Health Action Plan, a new digital tool for 23andMe+ members that draws on results from genetic reports, health history ...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial resu...
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading genetic health and biopharmaceutical company, in collaboration with 20 lung cancer advocacy organizations, today announced a new study to help advance research in lung cancer. The focus of the Lun...